ea0089c11 | Clinical – Chemo/SSA/Biologics | NANETS2022
Fuchs Orenbach Shir
, Haviv Asi
Background: Oral octreotide capsules (OOC) are approved in the United Sates for long-term maintenance treatment in acromegaly patients who have previously responded to and tolerated injectable somatostatin analogs (SSAs, octreotide or lanreotide). Injectable SSAs are also approved and the standard of care in the treatment of carcinoid syndrome associated with neuroendocrine tumors (NET). Compared with acromegaly, patients with NET can require higher average doses of injectable...